Other Events ·
Quince Therapeutics received a notice from Nasdaq on August 31, 2026, for failing to meet the $10 million minimum…
QNCXIRulya Therapeutics Inc.
Quince Therapeutics received a notice from Nasdaq on August 31, 2026, for failing to meet the $10 million minimum stockholders' equity requirement, citing a deficit of ($35.3 million) as of June 30, 2026. The company has until October 15, 2026, to submit a compliance plan and may receive an extension until February 27, 2027. Quince is evaluating alternatives to regain compliance and references a pending listing application that could result in a name change to IRulya Therapeutics Inc. and a transfer to the Nasdaq Capital Market under the symbol IRLA. The company operates in the biotechnology industry.